Welcome to the international HTA database

Showing [20829 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Testosterone reference ranges for gender diverse individuals
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Breast cancer risk assessment tools
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022	Norwegian Institute of Public Health (NIPH)	Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022	Norwegian Institute of Public Health (NIPH)	[Operating room ventilation: a health technology assessment]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022	Health Information and Quality Authority (HIQA)	Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: classification of thickened liquids for dysphagia]
2022	Health Information and Quality Authority (HIQA)	HTA of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2022	NIHR Health Technology Assessment programme	Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: primary care and service quality indicators for supporting continuous quality improvement in Québec’s family medicine groups]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: a look at Québec’s family medicine groups and a proposal to segment the population to support continuous quality improvement approaches based on health needs]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: organization of medical care and services in long-term care facilities]
2022	NIHR Public Health Research (PHR) programme	E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022	NIHR Health Technology Assessment programme	Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Restrictive red blood cell (RBC) transfusion thresholds: update
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of Afstyla™ (rFVIII) – type A hemophilia]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: biologic dose escalation - gastroenterology, rheumatology and dermatology]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: amyotrophic lateral sclerosis with or without frontotemporal dementia NGS panel]
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022	NIHR Health Technology Assessment programme	Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022	NIHR Health Technology Assessment programme	Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: next-generation sequencing (NGS) panels for muscle disease]
2022	Scottish Health Technologies Group (SHTG)	Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2022	NIHR Health Technology Assessment programme	Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022	NIHR Health Technology Assessment programme	Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review
2022	NIHR Health Technology Assessment programme	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Workplace violence in healthcare settings
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: integration of real-world data and evidence into assessments to support decision-making in the pharmaceutical sector]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intraocular lens implantation for infants with aphakia: a systematic review of clinical effectiveness and cost-effectiveness
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peer support programs for youth mental health
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Optimal pharmacotherapy for transplant ineligible multiple myeloma
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Rituximab for the treatment of primary membranous nephropathy
2022	NIHR Health Technology Assessment programme	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022	Norwegian Institute of Public Health (NIPH)	Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022	Swiss Federal Office of Public Health (FOPH)	Thyroid function tests for the diagnosis of suspected primary or secondary thyroid dysfunction
2022	Swiss Federal Office of Public Health (FOPH)	Medicines for dementia due to Alzheimer's disease and Parkinson's disease
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Promoting mental well-being in children and adolescents]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Post COVID-19 – effective treatment and rehabilitation]
2022	Norwegian Institute of Public Health (NIPH)	Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2022	Swiss Federal Office of Public Health (FOPH)	Levothyroxine as a treatment for subclinical hypothyroidism
2022	Swiss Federal Office of Public Health (FOPH)	Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022	Swiss Federal Office of Public Health (FOPH)	Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022	Swiss Federal Office of Public Health (FOPH)	Denosumab (Prolia®) for the treatment of osteoporosis
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatment of hyperemesis (severe nausea during pregnancy)]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Return to work – persons with long-term sickleave or welfare recipients
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatment of women with diastasis recti]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Wheelchairs and wheelchair accessories]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Food in diabetes]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Occupational exposure and upper extremity pain]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Bronchial thermoplasty in severe asthma]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2022	Ontario Health	Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022	Health Technology Wales (HTW)	Virtual reality interventions for the management of pain associated with medical procedures
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home-based oral nutritional supplements in cancer patients with moderate-severe malnutrition undergoing active treatment]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022	NIHR Health Technology Assessment programme	Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT
2022	NIHR Health Technology Assessment programme	RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022	NIHR Health Technology Assessment programme	E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC PC)
2022	NIHR Health Technology Assessment programme	The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury
2022	NIHR Health Technology Assessment programme	Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest (Airways-2)
2022	NIHR Health Technology Assessment programme	Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
2022	NIHR Health Technology Assessment programme	PUMA - Paediatric early warning system (PEWS): Utilisation and Mortality Avoidance. A prospective, mixed methods, before and after study identifying the evidence base for the core components of an effective PEWS and the development of an implementation package for implementation and use in the UK
2022	NIHR Health Technology Assessment programme	StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): A randomised, double-masked, sham- controlled, clinical trial comparing low-voltage X-ray irradiation with as needed ranibizumab, to as needed ranibizumab monotherapy
2022	NIHR Health Technology Assessment programme	At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK (ARRISA-UK): a pragmatic cluster randomised trial with nested economic and process evaluations examining the effects of integrating at-risk asthma registers into primary care with internet-based training and support
2022	NIHR Health Technology Assessment programme	Cerclage Suture Type for an Insufficient Cervix and its effect on Health outcomes (C-STICH)
2022	NIHR Health Technology Assessment programme	The effectiveness of adjunctive medication management and contingency management to enhance adherence to medications for relapse prevention in alcohol dependence
2022	NIHR Health Technology Assessment programme	Catheter Ablation versus thoracoscopic Surgical Ablation in long standing persistent Atrial Fibrillation (CASA-AF)
2022	NIHR Health Technology Assessment programme	Intravenous immunoglobulin in the management of encephalitis in children
2022	NIHR Health Technology Assessment programme	Early detection of neovascular age-related macular degeneration
2022	NIHR Health Technology Assessment programme	Comparison of ALitretinoin with PUVA as the first line treatment in patients with severe chronic HAnd eczema (ALPHA trial)
2022	NIHR Health Technology Assessment programme	Liaison Psychiatry: Measurement And Evaluation of Service Types, Referral patterns and Outcomes LP-MAESTRO
2022	NIHR Health Technology Assessment programme	VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot. The VIOLET Study
2022	NIHR Health Technology Assessment programme	Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment
2022	NIHR Health Technology Assessment programme	Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022	NIHR Health Technology Assessment programme	The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome
2022	NIHR Health Technology Assessment programme	Development and evaluation of machine learning methods in whole body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer (MAchine Learning In whole Body Oncology, MALIBO)
2022	NIHR Health Technology Assessment programme	Enhancing social-emotional health and wellbeing in the early years: a community-based randomised controlled trial (and economic) evaluation of the Incredible Years Infant and Toddler (0-2) Parenting Programmes
2022	NIHR Health Technology Assessment programme	Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): a randomised placebo-controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
2022	NIHR Health Technology Assessment programme	Delivering primary health care to homeless people: an evaluation of the integration, effectiveness and costs of different models